Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) saw a downside of -2.80% to $0.23 after subtracting $0.0 on Monday. The 5-day average trading volume is 800,815 shares of the company’s common stock. It has gained $0.2470 in the past week and touched a new high 3 times within the past 5 days. An average of 4,354,239 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,053,874.
PIRS’s 1-month performance is 36.78% or $0.0578 on its low of $0.1680 reached on 07/10/23. The company’s shares have touched a 52-week low of $0.16 and high of $1.97, with the stock’s rally to the 52-week high happening on 02/02/23. YTD, PIRS has lost -78.04% or -$0.8152 and has reached a new high 12 times. However, the current price is down -88.40% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
PIRS stock has a beta of 0.81. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1.07 while the price-to-book (PB) in the most recent quarter is 1.09.
Pieris Pharmaceuticals Inc.’s quick ratio for the period ended March 30 was 1.40, with the current ratio over the same period at 1.40. The firm’s gross profit as reported stood at $69.38 million against revenue of $25.9 million.
Earnings Surprise
For the quarterly period ending March 30 this year, Pieris Pharmaceuticals Inc.’s cash and short-term investments amounted to $8.64 million against total debt of $13.09 million. Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 61.31% to -$13.18 million, while revenue of -$8.1 million was 38.54% off the previous quarter. Analysts expected PIRS to announce -$0.14 per share in earnings in its latest quarter, but it posted -$0.18, representing a -28.60% surprise. EBITDA for the quarter stood at more than -$14.91 million. PIRS stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 66.8 million, with total debt at $13.09 million. Shareholders hold equity totaling $82.02 million.
Let’s look briefly at Pieris Pharmaceuticals Inc. (PIRS) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 04 August was 46.56% to suggest the stock is trending Neutral, with historical volatility in this time period at 58.58%.
The stock’s 5-day moving average is $0.2256, reflecting a +1.72% or $0.0038 change from its current price. PIRS is currently trading +23.52% above its 20-day SMA, -84.06% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -74.71% and SMA200 by-78.38%.
Stochastic %K and %D was 37.54% and 27.34% and the average true range (ATR) pointed at 0.0266. The RSI (14) points at 37.84%, while the 14-day stochastic is at 61.70% with the period’s ATR at 0.0342. The stock’s 9-day MACD Oscillator is pointing at 0.0085 and 0.0095 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Pieris Pharmaceuticals Inc. (NASDAQ: PIRS), Robert W. Baird upgraded it to an Outperform rating. They previously had a Neutral rating on the stock. Analysts offering their rating for PIRS stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate PIRS as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is PIRS’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $7.00 and a high of $7.00, with their median price target at $7.00. Looking at these predictions, the average price target given by analysts is for Pieris Pharmaceuticals Inc. (PIRS) stock is $7.00.
